MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Velox Therapeutics

Thrombosis is a leading cause of death in developed countries. The currently used antithrombotics are associated with an increased risk of severe bleeding, which can be life threatening. The inhibition of a novel target, FXI, was found to efficiently prevent thrombosis without causing bleeding side effects, providing a much safer strategy. We have developed the first peptide-based FXI inhibitor, which shows a superior anti-coagulation effect, lasting for more than 10 hours in mice.
We have developed a novel anticoagulant that does not increase the bleeding risk, thus overcoming the safety issues related to current drugs

Connect with Velox Therapeutics

Velox Therapeutics

2018

2018 Platinum Switzerland

Sub industry

Therapeutics (Pharma / Biotech)

Mission

Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.